Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
We identified a subset of genes involved in chromatin remodeling whose mRNA expression changes in differentiating mouse erythroleukemia (MEL) cells. We furthermore tested their mRNA expression patterns in normal and malignant CD34+ bone marrow cells. SMARCA5, imitation switch gene homologue, was rapidly silenced during in vitro erythroid differentiation of MEL cells whereas it was up-regulated in CD34+ hematopoietic progenitors of acute myeloid leukemia (AML) patients. Moreover, SMARCA5 mRNA levels decreased in AML CD34+ progenitors after the patients achieved complete hematologic remission. We detected high levels of SMARCA5 mRNA in murine bone marrow and spleen and monitored its expression in these hematopoietic tissues during accelerated hematopoiesis following hemolytic anemia induced by phenylhydrazine. SMARCA5 expression levels decreased after the onset of accelerated erythropoiesis. Our data suggest that both in vitro and in vivo induction of differentiation is followed by down-regulation of SMARCA5 expression. In CD34+ AML progenitors over-expression of SMARCA5 may thus dysregulate the genetic program required for normal differentiation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SMARCA5, an ATP-dependent chromatin remodeler recruited to Pu.1 in Runx1-deficient cells and which is overexpressed in primary AML (42”
From Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy (2014) · cites this paper as [42]
Citations
Cites
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Gene Expression Profiles in Normal and Cancer Cells
Zhang, L., Zhou, W., Velculescu, V. E., Kern, S. E., Hruban, R. H., Hamilton, S. R., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.276.5316.1268 · Cited by 1,184
ATP-dependent remodeling and acetylation as regulators of chromatin fluidity
Kingston, R. E., & Narlikar, G. J. (1999) · Genes & Development · doi:10.1101/gad.13.18.2339 · Cited by 702
Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II
Varga-Weisz, P. D., Wilm, M., Bonte, E., Dumas, K., Mann, M., & Becker, P. B. (1997) · Nature · doi:10.1038/41587 · Cited by 513
Rekhtman, N., Radparvar, F., Evans, T., & Skoultchi, A. I. (1999) · Genes & Development · doi:10.1101/gad.13.11.1398 · Cited by 454
Structure, function, and activation of the erythropoietin receptor
Youssoufian, H., Longmore, G., Neumann, D., Yoshimura, A., & Lodish, H. (1993) · Blood · doi:10.1182/blood.v81.9.2223.2223 · Cited by 355
Fox, A. H., Liew, C., Holmes, M., Kowalski, K., Mackay, J., & Crossley, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.10.2812 · Cited by 270
ISWI Is an ATP-Dependent Nucleosome Remodeling Factor
Corona, D. F. V., Längst, G., Clapier, C. R., Bonte, E. J., Ferrari, S., Tamkun, J. W., & Becker, P. B. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80314-7 · Cited by 239
Fibach, E., Reuben, R. C., Rifkind, R. A., & Marks, P. A. (1977) · PubMed · Cited by 190
Chromatin Remodeling and Leukemia: New Therapeutic Paradigms
Redner, R. L., Wang, J., & Liu, J. M. (1999) · Blood · doi:10.1182/blood.v94.2.417 · Cited by 189
Cited by
ATP-dependent chromatin remodeling in the DNA-damage response
Lans, H., Marteijn, J. A., & Vermeulen, W. (2012) · Epigenetics & Chromatin · doi:10.1186/1756-8935-5-4 · Cited by 212
“Both ATP-dependent chromatin remodeling [152-155] and the DDR [3,5] are implicated in tumorigenesis, but their interplay in this process is still not understood.”
BackgroundThe ISWI ATPase Snf2h is required for early mouse development
Stopka, T., & Skoultchi, A. I. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336105100 · Cited by 203
Self-citationThe Chromatin Response to DNA Breaks: Leaving a Mark on Genome Integrity
Smeenk, G., & van Attikum, H. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061809-174504 · Cited by 127
The emerging role of ISWI chromatin remodeling complexes in cancer
Li, Y., Gong, H., Wang, P., Zhu, Y., Peng, H., Cui, Y., Li, H., Liu, J., & Wang, Z. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02151-x · Cited by 123
Lazzaro, M. A., & Picketts, D. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00324.x · Cited by 99
“Interestingly, the elevated expression of Snf2h mRNA in proliferating cells and its subsequent downregulation in differentiated cells that we have described has also been observed when CD34(1) hematopoietic progenitors of acute myeloid leukemia patients undergo remissionassociated differentiation (Stopka et al. 2000).”
BackgroundDaxinger, L., Harten, S. K., Oey, H., Epp, T., Isbel, L., Huang, E., Whitelaw, N., Apedaile, A., Sorolla, A., Yong, J., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-9-r96 · Cited by 92
“MommeD4 Enhancer Smarca5 T->A exon 12; W520R Hypomorphic? [5,6] SMARCA5 Acute myeloid leukemia [20]”
Acfs: accurate circRNA identification and quantification from RNA-Seq data
You, X. A., & Conrad, T. (2016) · Scientific Reports · doi:10.1038/srep38820 · Cited by 99
“We then asked whether circRNA profiles could be used for molecular disease stratification and we identified thousands of circRNAs, using acfs, in five APL samples 16 and five CN-AML samples 31 .”
BackgroundInfluentialWang, Z., Wang, P., Li, Y., Peng, H., Zhu, Y., Mohandas, N., & Liu, J. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00422-1 · Cited by 85
“After complete hematologic remission, SNF2H levels decreased, suggesting that overexpression of SNF2H may dysregulate the genetic program required for normal differentiation.(55) Moreover, the SNF2H/CTCF binding site at the PU.”
BackgroundMohamed, M. A., Greif, P. A., Diamond, J., Sharaf, O., Maxwell, P., Montironi, R., Young, R. A. M., & Hamilton, P. W. (2007) · BJU International · doi:10.1111/j.1464-410x.2006.06704.x · Cited by 74
Human SMARCA5 is continuously required to maintain nucleosome spacing
Bomber, M. L., Wang, J., Liu, Q., Barnett, K. R., Layden, H. M., Hodges, E. C., Stengel, K. R., & Hiebert, S. W. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.018 · Cited by 60
Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p
Liu, H., Wu, Y., Wang, S., Jiang, J., Zhang, C., Jiang, Y., Wang, X., Hong, L., & Huang, H. (2019) · BMC Cancer · doi:10.1186/s12885-019-6088-0 · Cited by 59
Overexpression of SMARCA5 correlates with cell proliferation and migration in breast cancer
Jin, Q., Mao, X., Li, B., Guan, S., Yao, F., & Jin, F. (2014) · Tumor Biology · doi:10.1007/s13277-014-2791-2 · Cited by 58
Hosur, R., Xu, J., Bienkowska, J., & Berger, B. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.11.025 · Cited by 57
“Furthermore, iWRAP predicts an interaction between XPA (RAD14) and SMARCA5; the latter has been shown to be critical for regulating the genetic program required for normal differentiation[63].”
BackgroundKokavec, J., Zikmund, T., Savvulidi, F. G., Kulvait, V., Edelmann, W., Skoultchi, A. I., & Stopka, T. (2017) · Stem Cells · doi:10.1002/stem.2604 · Cited by 56
Self-citationSophisticated Conversations between Chromatin and Chromatin Remodelers, and Dissonances in Cancer
Clapier, C. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115578 · Cited by 50
“Interestingly, in acute myeloid leukemia (AML) patients, CD34+ hematopoietic progenitors show SNF2H upregulation [248], which can be drug-inhibited to release terminal-differentiation while sparing normal hematopoiesis [249].”
BackgroundGu, X., Hu, Z., Ebrahem, Q., Crabb, J. S., Mahfouz, R. Z., Radivoyevitch, T., Crabb, J. W., & Saunthararajah, Y. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.562447 · Cited by 42
“Yet, the AML cells are differentiation arrested by morphology and demonstrate epigenetic repression of key differentiation target genes of these same transcription factors (20, 27–29).”
BackgroundInfluentialSMARCA5Methylation and Expression in Gastric Cancer
Gigek, C. O., Lisboa, L. C. F., Leal, M. F., Silva, P. N., Lima, E. M., Khayat, A. S., de Assumpção, P. P., Burbano, R. M. R., & Smith, M. D. A. C. (2011) · Cancer Investigation · doi:10.3109/07357907.2010.543365 · Cited by 42
“SMARCA5 is generally associated with cell proliferation and viability (15, 18, 19).”
BackgroundNucleosome Remodeler SNF2L Suppresses Cell Proliferation and Migration and Attenuates Wnt Signaling
Eckey, M., Kuphal, S., Straub, T., Rümmele, P., Kremmer, E., Bosserhoff, A., & Becker, P. B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06619-11 · Cited by 40
“explored the relationship between SNF2H expression and hematopoietic progenitor cell differentiation and found higher levels of SNF2H in CD34 progenitors of acute myeloid leukemia (AML) patients, which decreased after complete hematologic remission of the tumor (44).”
BackgroundEphB6 Receptor Modulates Micro RNA Profile of Breast Carcinoma Cells
Bhushan, L., & Kandpal, R. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022484 · Cited by 38
“SMARCC1 is altered in prostate and colorectal cancer [23] and SMARCA5 is known to be dysregulated in leukemia [24] and upregulated in human breast tumors [25].”
BackgroundEpigenetic Control of SPI1 Gene by CTCF and ISWI ATPase SMARCA5
Dluhošová, M., Čuřík, N., Vargova, J., Jonasova, A. T., Zikmund, T., & Stopka, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087448 · Cited by 35
“It is known that Smarca5 is overexpressed in leukemic cells including MEL cells [10].”
BackgroundSelf-citationIdentification of cell-specific targets of sumoylation during mouse spermatogenesis
Xiao, Y., Pollack, D., Andrusier, M. A., Levy, A., Callaway, M. B., Nieves, E., Reddi, P. P., & Vigodner, M. (2016) · Reproduction · doi:10.1530/rep-15-0239 · Cited by 36
Nm23‐H1 inhibits lung cancer bone‐specific metastasis by upregulating miR‐660‐5p targeted SMARCA5
Ai, C., Ma, G., Deng, Y., Zheng, Q., Gen, Y., Li, W., Yang, L., Zu, L., & Zhou, Q. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13308 · Cited by 33
Alrfaei, B. M., Clark, P. A., Vemuganti, R., & Kuo, J. S. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820960748 · Cited by 30
Mutual Regulation of ncRNAs and Chromatin Remodeling Complexes in Normal and Pathological Conditions
Bure, I. V., & Nemtsova, M. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097848 · Cited by 29
“It was also frequently overexpressed in acute myeloid leukemia [31] and breast cancer, where it was positively correlated with tumor size, TNM stage, and a poor overall survival [32].”
BackgroundMass Spectrometric Studies on Epigenetic Interaction Networks in Cell Differentiation
Xiong, L., Darwanto, A., Sharma, S., Herring, J. L., Hu, S., Filippova, M., Filippov, V. A., Wang, Y., Chen, C.-S., Duerksen-Hughes, P. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.204800 · Cited by 29
Zhao, Y., Wang, Z., Hou, Y., Zhang, K., & Peng, X. (2017) · Gene · doi:10.1016/j.gene.2017.06.039 · Cited by 28
High-throughput transcription profiling identifies putative epigenetic regulators of hematopoiesis
Prasad, P., Rönnerblad, M., Arner, E., Itoh, M., Kawaji, H., Lassmann, T., Daub, C. O., Forrest, A. R. R., Lennartsson, A., & Ekwall, K. (2014) · Blood · doi:10.1182/blood-2013-02-483537 · Cited by 31
Thakur, S., Cahais, V., Turková, T., Zikmund, T., Renard, C., Stopka, T., Korenjak, M., & Zavadil, J. (2022) · Cells · doi:10.3390/cells11050808 · Cited by 25
“Smarca5 is frequently overexpressed in different cancer types, including glioma [24], leukemia [25], breast [26,27] and gastric [28] cancer.”
BackgroundSelf-citationZikmund, T., Paszeková, H., Kokavec, J., Kerbs, P., Thakur, S., Turková, T., Tauchmanová, P., Greif, P. A., & Stopka, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062073 · Cited by 24
“SMARCA5 overexpression has been also observed in AML CD34+ progenitors [7,19].”
BackgroundResultSelf-citationThe Roles of SNF2/SWI2 Nucleosome Remodeling Enzymes in Blood Cell Differentiation and Leukemia
Prasad, P., Lennartsson, A., & Ekwall, K. (2015) · BioMed Research International · doi:10.1155/2015/347571 · Cited by 28
“The AML blast cells highly express SMARCA5, and its expression goes down upon treatment [95].”
BackgroundDOT1L bridges transcription and heterochromatin formation at mammalian pericentromeres
Malla, A. B., Yu, H., Farris, D., Kadimi, S., Lam, T. T., Cox, A. L., Smith, Z. D., & Lesch, B. J. (2023) · EMBO Reports · doi:10.15252/embr.202256492 · Cited by 23
Li, Z., Zhu, M., Du, J., Ma, H., Jin, G., & Dai, J. (2018) · BMC Genomics · doi:10.1186/s12864-018-5142-7 · Cited by 23
MiR-146b-5p suppresses the malignancy of GSC/MSC fusion cells by targeting SMARCA5
Wang, H., Tan, L., Dong, X., Liu, L., Jiang, Q., Li, H., Shi, J. Y., Yang, X., Dai, X., Qian, Z., et al. (2020) · Aging · doi:10.18632/aging.103489 · Cited by 20
“2 bands of chromosome 4 [57] and is regarded as a critical contributor to malignant tumors, such as gastric cancer [58], acute leukemia [59] and prostate cancer [60, 61], among others, where SMARCA5 is significantly upregulated and shown to promote cancer progression [62–64].”
BackgroundZhao, X., An, P., Wu, X., Zhang, L., Long, B., Tian, Y., Chi, X., & Tong, D. (2015) · Tumor Biology · doi:10.1007/s13277-015-4579-4 · Cited by 18
Li, L., Zhu, H., Li, X., Ke, Y., Yang, S., & Cheng, Q. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.12.008 · Cited by 15
“[39] Stopka T, Zakova D, Fuchs O, Kubrova O, Blafkova J, Jelinek J, et al.”
BackgroundChromatin remodeling and SWI/SNF2 factors in human disease
Kokavec, J., Podskocova, J., Zavadil, J., & Stopka, T. (2008) · Frontiers in bioscience · doi:10.2741/3142 · Cited by 14
“Study of hematopoietic progenitors in acute leukemia identified an increase in SNF2H expression that correlated with status of the disease and decreased after the patients achieved complete therapy-induced hematologic remission (44).”
BackgroundWei, X., Feng, Y., Fu, Y., Liu, F., Chen, Q., Zhang, W., Zhao, Y., Huang, X., Chen, Y., Li, Q., et al. (2023) · Hematology · doi:10.1080/16078454.2023.2196857 · Cited by 12
Wang, Y., Qin, J., Liu, Q., Hong, X., Li, T., Zhu, Y., He, L., Zheng, B., & Li, M. (2016) · Oncology Letters · doi:10.3892/ol.2016.4681 · Cited by 13
ANP32B suppresses B‐cell acute lymphoblastic leukemia through activation of PU .1 in mice
Yang, Q., Liu, H., Yang, S., Wei, Y., Zhu, X., Zhi, Z., Zhu, D., Chen, G., & Yu, Y. (2023) · Cancer Science · doi:10.1111/cas.15822 · Cited by 11
The Impact of Biology on the Treatment of Secondary AML
Gojo, I., & Karp, J. E. (2001) · Cancer treatment and research · doi:10.1007/978-1-4615-1463-3_12 · Cited by 12
Research Progress on MicroRNAs Involved in the Regulation of Chicken Diseases
Wang, Y. (2019) · The Journal of Poultry Science · doi:10.2141/jpsa.0190073 · Cited by 9
“also been reported that SMARCA5 plays an important role in promoting cell proliferation both in vitro and in vivo (Stopka et al., 2000; Gigek et al., 2011).”
BackgroundThe role of epigenetic modifications in hematological cancers
Ilic, J., Bold, A., & Knop, S. T. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1744018 · Cited by 4
SMARCA5-mediated chromatin remodeling is required for germinal center formation
Stoler‐Barak, L., Schmiedel, D., Sarusi-Portuguez, A., Rogel, A., Blecher‐Gonen, R., Haimon, Z., Stopka, T., & Shulman, Z. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240433 · Cited by 5
“Recent studies have implicated SMARCA5 in the progression of several cancer types including blood cancer (Jin et al., 2015; Thakur et al., 2022; Stopka et al., 2000; Zikmund et al., 2020; Radzisheuskaya et al., 2023; Bayona-Feliu et al., 2023; Gigek et al., 2011).”
Self-citationNuclear localization of ISWI ATPase Smarca5 Snf2h in mouse
Stopka, T. (2009) · Frontiers in Bioscience-Elite · doi:10.2741/e53 · Cited by 4
“Localization of Smarca5 and Brg1 in euchromatin supports their role in transcription regulation of actively transcribed genes in euchromatin (2, 7, 14, 15).”
BackgroundMethodSelf-citationRIOK1 : A Novel Oncogenic Driver in Hepatocellular Carcinoma
Ruan, C., Shang, T., Zhang, S., Ru, W., Yang, Y., & Shen, Y. (2025) · Cancer Medicine · doi:10.1002/cam4.70597 · Cited by 3
“It is highly expressed in various tumors, such as leukemia [41, 42], glioma [43], breast [44, 45], and gastric cancers [46].”
Hoffmeister, H., Fuchs, A., Komives, E. A., Gröbner-Ferreira, R., Strobl, L., Nazet, J., Heizinger, L., Merkl, R., Dove, S., & Längst, G. (2021) · FEBS Journal · doi:10.1111/febs.15699 · Cited by 2
Pannérer, M.-M. L., Diesch, J., Casquero, R., Maher, M., García, O., Haferlach, T., Zuber, J. A., Kündgen, A., Götze, K. S. S., & Buschbeck, M. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000792 · Cited by 1
Timoszczuk, L. M. S. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2012.tde-13122012-162235
Colin, C. (2006) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2006.tde-06102015-184842 · Cited by 1
Chromatin remodeling in the UV-induced DNA damage response
Aydın, Ö. Z. (2014) · RePub (Erasmus University Rotterdam)
Chromatin Remodeling in Cervical Tumor Cells Regulates Proangiogenic Genes
Bhat, S. M., Simha, N. L., Hegde, S., & Joshi, M. B. (2025) · Springer eBooks · doi:10.1007/978-981-96-3985-4_6
Localization mechanism and significance of histone H3 lysine 36 dimethylation on heterochromatin
後藤, 尚., & Goto, N. (2024) · Institutional Repositories DataBase (IRDB)
Metadata
- Authors
- Stopka, T., Zakova, D., Fuchs, O., Kubrova, O., Blafkova, J., Jelinek, J., Necas, E., & Zivny, J.
- Affiliations
- Charles University (CZ)
- Venue
- Leukemia
- Published
- 2000-07-01
- Volume
- 14
- Issue
- 7
- Pages
- 1247-1252
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2329719572
- Cited by
- 51
- References
- 24
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 5 · 2013: 2 · 2012: 3
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- SMARCA5, chromatin remodeling, acute myeloid leukemia, erythroid differentiation, erythroleukemia cells, CD34+ hematopoietic progenitor cells, gene expression regulation, complete hematologic remission, hematopoiesis
- MeSH terms
- Acute Disease, Anemia, Hemolytic, Animals, Bone Marrow, Cell Differentiation, Chromatin, DNA Topoisomerases, Type II, Leukemia, Erythroblastic, Acute, Hematopoiesis, Hematopoietic Stem Cells, High Mobility Group Proteins, Humans, Leukemia, Myeloid, Mice, Inbred C3H, Neoplasm Proteins, Phenylhydrazines, RNA, Messenger, RNA, Neoplasm, Spleen, Subtraction Technique, Tumor Cells, Cultured, Neoplastic Stem Cells, Erythroid Precursor Cells, Gene Expression Regulation, Leukemic, Gene Expression Profiling, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.